|
|||||
|
|
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo‐hormonal therapy |
|
| Authors: | Pedro Barata MD MSc Hamid Emamekhoo MD Prateek Mendiratta MD Vadim Koshkin MD Allison Tyler Moshe Ornstein MD MSc Brian I. Rini MD FACP Timothy Gilligan MD FACP Christos Kyriakopoulos MD Jorge A. Garcia MD |
| Affiliation: | 1. Department of Hematology and Medical Oncology, Taussig Cancer Institute Cleveland Clinic, Cleveland, Ohio;2. Department of Medicine, Division of Hematology and Oncology Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health , Madison, Wisconsin |
| Abstract: | |
| Keywords: | chemo‐hormonal therapy docetaxel hormone‐sensitive prostate cancer second‐generation hormonal therapy subsequent therapies |